Zynex Receives Deloitte Technology Fast 500 Award for the 5th Consecutive Year in 2023!

Share This Post

Tech News Summary:

  • Zynex, Inc. has been named as a winner in the Deloitte 2023 Technology Fast 500 Awards for the 5th consecutive year, recognizing its outstanding growth and performance.
  • The company’s revenue grew by an impressive 248% between 2019 and 2022, reaching $158.2 million in 2022. For 2023, Zynex estimates its revenue to be between $189.5 million and $194.5 million.
  • Focused on developing, manufacturing, marketing, and selling medical devices for pain treatment and rehabilitation, Zynex has been recognized for its commitment to transformation and creating a thriving business, as well as its ongoing revenue and profit growth.

Zynex Wins Deloitte 2023 Technology Fast 500 Award for 5th Year Running!

Zynex, a leading developer and manufacturer of non-invasive medical devices for pain management and rehabilitation, has been recognized once again for its impressive growth and innovation. The company has been named a winner of the prestigious Deloitte 2023 Technology Fast 500 Award for the fifth consecutive year.

The Deloitte Technology Fast 500 program recognizes the fastest-growing technology companies in North America, based on percentage fiscal year revenue growth over a three-year period. Zynex’s consistent presence on the list is a testament to the company’s sustained success and commitment to advancing the field of medical technology.

“We are honored to once again be recognized by Deloitte for our growth and innovation,” said Thomas Sandgaard, CEO of Zynex. “This award is a reflection of our dedicated team and our relentless pursuit of excellence in developing life-changing medical devices. We are proud to be at the forefront of the industry and look forward to continuing our growth in the years to come.”

Zynex’s continued success can be attributed to its focus on delivering high-quality, cost-effective medical devices that meet the needs of patients and healthcare providers. The company’s flagship products, including electrotherapy and neuromuscular stimulation devices, have gained widespread acceptance and have contributed to its sustained growth.

As Zynex secures its fifth consecutive Deloitte Technology Fast 500 Award, the company looks ahead to the future with excitement and optimism. With a strong track record of success and a commitment to innovation, Zynex is well positioned to continue its growth and make a lasting impact in the world of medical technology.

Read More:

Related Posts